Population-Based Epidemiology, Malignancy Risk, and Outcome of Primary Sclerosing Cholangitis by Boonstra, K. et al.
AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE
Population-Based Epidemiology, Malignancy Risk, and
Outcome of Primary Sclerosing Cholangitis
Kirsten Boonstra,1 Rinse K. Weersma,2 Karel J. van Erpecum,3 Erik A. Rauws,1 B.W. Marcel Spanier,4
Alexander C. Poen,5 Karin M. van Nieuwkerk,6 Joost P. Drenth,7 Ben J. Witteman,8 Hans A. Tuynman,9
Anton H. Naber,10 Paul J. Kingma,10 Henk R. van Buuren,11 Bart van Hoek,12 Frank P. Vleggaar,3
Nan van Geloven,13 Ulrich Beuers,1 and Cyriel Y. Ponsioen,1 on behalf of the EpiPSCPBC Study Group
Extensive population-based studies are much needed to accurately establish epidemiology
and disease course in patients with primary sclerosing cholangitis (PSC). We aimed to obtain
population-based prevalence and incidence figures, insight in disease course with regard to
survival, liver transplantation (LT), and occurrence of malignancies, as well as risk factors
thereof. Four independent hospital databases were searched in 44 hospitals in a large
geographically defined area of the Netherlands, comprising 50% of the population. In addi-
tion, all PSC patients in the three Dutch liver transplant centers and all inflammatory bowel
disease (IBD) patients in the adherence area of a large district hospital were identified. All
medical records were reviewed on-site, verifying diagnosis. Five hundred and ninety PSC
patients were identified, resulting in an incidence of 0.5 and a point prevalence of 6.0 per
100,000. Median follow up was 92 months. Estimated median survival from diagnosis until
LT or PSC-related death in the entire cohort was 21.3 years, as opposed to 13.2 years in the
combined transplant centers cohort (n 5 422; P < 0.0001). Colorectal carcinoma (CRC)
risk was 10-fold increased, as compared to ulcerative colitis controls, and developed at a
much younger age (39 years; range, 26-64), compared to IBD controls (59 years; range,
34-73; P 5 0.019). Colonoscopic surveillance was associated with significantly better out-
come. Conclusion: This study exemplifies that, for relatively rare diseases, it is paramount to
collect observational data from large, population-based cohorts, because incidence and prev-
alence rates of PSC are markedly lower and survival much longer than previously reported.
The selection of a bias-free, population-based cohort showed a significantly longer survival,
compared to the tertiary referral cohort. CRC can develop at an early age, warranting sur-
veillance from time of PSC diagnosis. (HEPATOLOGY 2013;58:2045-2055)
P
rimary sclerosing cholangitis (PSC) is an enig-
matic cholestatic liver disease affecting the intra-
and extrahepatic bile ducts. PSC is more com-
mon in men than in women (2:1) and can occur at
any age, with a peak incidence around 40.1 Common
symptoms associated with PSC are jaundice, pruritus,
and upper abdominal discomfort, although approxi-
mately 40% of patients are asymptomatic at
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diagnosis.2 Multifocal strictures and dilatations of the
intra- and/or extrahepatic bile ducts noted on cholan-
giography are hallmarks of PSC.3 PSC is strongly asso-
ciated with inflammatory bowel diseases (IBDs), and
patients are at increased risk for developing colorectal
and biliary malignancies.4,5 Disease course is highly
variable and there is no treatment available with pro-
ven efficacy in halting disease progression other than
liver transplantation (LT). In Europe, PSC accounts
for 9% of LT indications.6 Median survival time until
death or liver transplantation is reported to be 12
years.2,7-9
Most epidemiological studies on PSC are retrospec-
tive case series mainly describing disease course and
the association with IBD based on tertiary referral
series with their immanent selection bias. Large,
population-based data on incidence and prevalence as
well as on the natural history of PSC are scarce, but
very important for proper patient counseling, finding
clues to etiology, as well as for healthcare officials deal-
ing with the planning of future budgets for LT, which
is currently one of the most expensive treatments avail-
able, averaging $120,000.
Here, we describe the largest comprehensive PSC
cohort to date to obtain proper population-based prev-
alence and incidence figures, insight in disease course
with regard to survival, need for LT, and occurrence of
PSC-related malignancies, as well as risk factors
thereof.
Patients and Methods
Study Design and Participants. The protocol was
approved by the central Committee for Research
Ethics in Utrecht and all 44 local ethics committees of
the participating hospitals in the Netherlands (trialre-
gister.nl no.: NTR2813). An observational longitudinal
cohort study was undertaken between January 1, 2008
and Decemeber 31, 2011. All PSC patients in 44 hos-
pitals from 2000 onward were identified in a geo-
graphically defined area of six adjacent provinces
comprising 50% of the Dutch population. These 44
hospitals provided care to the entire population of the
study area. PSC patients in the three liver transplant
centers in the Netherlands (University Medical Center
Groningen, Erasmus Medical Center Rotterdam, and
Leiden University Medical Center) and all IBD
patients without PSC in the adherence area of a large
district hospital (Tergooiziekenhuizen) served as con-
trol cohorts.5,10,11
Case Finding and Case Ascertainment. Case find-
ing was performed according to the guidelines of Met-
calf and James.12 Four independent hospital databases
were searched: (1) PALGA, a nationwide network and
comprehensive registry of histo- and cytopathology in
the Netherlands,13 using diagnosis code liver*biopsy*-
primary sclerosing cholangitis; (2) hospital billing sys-
tem using codes 707 (primary sclerosing cholangitis/
primary biliary cirrhosis/autoimmune hepatitis), 954
(primary sclerosing cholangitis/primary biliary cirrho-
sis) and 943 (autoimmune hepatitis) (International
Classification of Diseases, Tenth Revision code K83.0);
(3) endoscopic retrograde cholangiography (ERC)
reports in endoscopy-suite databases; and (4) personal
lists of treating physicians. IBD patients were searched
on-site using the same four data sources. PSC registries
in the three liver transplant centers in the Netherlands
and the IBD registry in the pertaining affiliated large
tertiary referral center were checked for missed referrals
from the area of interest. All medical records were
scrutinized on-site by two investigators (K.B. and C.P.)
for ascertainment of PSC diagnosis. Diagnosis was
based on the following: (1) clinical presentation (i.e.,
pruritus), pain in the right upper abdominal quadrant,
fatigue, weight loss, and episodes of fever; and/or (2)
elevated alkaline phosphatase and gamma-glutamyl
transferase, not otherwise explained; (3) presence of
characteristic bile duct changes with multifocal stric-
tures and segmental dilatations on ERC or magnetic
resonance cholangiography (MRC); and/or (4) liver
histology; and (5) no evidence for secondary sclerosing
cholangitis. When criteria 2, 4, and 5 were fulfilled in
the absence of cholangiographic abnormalities on
MRC or ERC, cases were diagnosed as small-duct PSC.14
Autoimmune hepatitis (AIH) overlap syndrome (PSC-
AIH) is ill defined. A diagnosis of PSC-AIH was made in
Address reprint requests to: Cyriel Y. Ponsioen, M.D., Ph.D., Department of Gastroenterology and Hepatology, Academic Medical Center, P.O. Box 22700,
1100 DE Amsterdam, the Netherlands. E-mail: c.y.ponsioen@amc.uva.nl; fax: 131 20 6917033.
Copyright VC 2013 by the American Association for the Study of Liver Diseases.
View this article online at wileyonlinelibrary.com.
DOI 10.1002/hep.26565
Potential conflict of interest: Dr. Beuers consults for Intercept and Novartis. He received lecture fees from the Falk Foundation, Roche, Gilead, and Zambon. Dr.
Ponsioen received grants from AbbVie, Falk, and Tramedico.
Additional Supporting Information may be found in the online version of this article.
2046 BOONSTRA ET AL. HEPATOLOGY, December 2013
patients with a characteristic cholangiogram who, in addi-
tion, met the simplified AIH criteria.15 IBD diagnosis
was based on the Lennard-Jones criteria.16
Data Collection. At study inclusion and during
follow-up, apart from demographic characteristics, the
following data and endpoints were collected: date and
type of PSC diagnosis; date of diagnosis and type of
IBD, including Montreal classification; date and cause
of death; date and type of malignancy; date and type of
surgery; and cumulative medication use 6 months for
ursodeoxycholic acid (UDCA), thiopurines, and mesal-
amine during follow-up. For nonsteroidal anti-
inflammatory drugs (NSAIDs), including aspirin, any
prescription use was counted. Date of PSC diagnosis is
defined as the date of the diagnostic procedure confirm-
ing the diagnosis (ERC, MRC, or liver biopsy). Colo-
noscopic surveillance was defined as a full colonoscopy
at PSC diagnosis and every 1-2 years after diagnosis in
PSC-IBD patients. Occurrence of carcinoma in the
cohort was double checked by linkage of the PSC
cohort to PALGA, the nationwide network and registry
of histo- and cytopathology in the Netherlands.13
Annual follow-up was obtained by written correspon-
dence from the treating physician. Date of diagnosis
was the starting point of follow-up. End of follow-up
was defined as death, last visit to outpatient clinic, or
end of the study (January 2012). PSC-related death was
defined as death caused by liver disease, cholangiocarci-
noma (CCA) or CRC. Date of death was retrieved
from the national death registry. Mid-year, age, and sex-
specific population estimates were based on data from
the Dutch Central Office for Statistics (http://statli-
ne.cbs.nl/statweb/). Data on the incidence of malignan-
cies in the general population were retrieved from the
Dutch Cancer Registry (www.cijfersoverkanker.nl).
Statistical Analyses. Date of diagnosis was defined
as the starting point of the disease for all analyses.
Cochrane-Armitage test for trend was used to test
changes in prevalence and incidence. Kaplan-Meier’s
survival analysis was performed to estimate cumula-
tive survival. Estimated median survival times were
calculated for (1) combined endpoint PSC-related
death or LT, (2) LT, and (3) PSC-related death cen-
sored at LT. Overall difference in survival was investi-
gated by the log-rank test. Standardized mortality
ratio (SMR) and standardized incidence ratio (SIR)
were calculated as the ratios of observed, compared
with expected, number of deaths and malignancies in
the study cohort. The expected number of patients
was calculated based on age- and gender-specific mor-
tality and malignancy rates in the general population.
When calculating cumulative risk and SIR for CCA,
censoring was performed for LT. In the case of dys-
plasia or CRC, cases were censored at time of colec-
tomy. The extended Cox model for time-dependent
(CCA, CRC, LT, and colectomy) and -independent
variables (age at diagnosis, gender, PSC type, AIH,
IBD, extension colitis, and medication) was used for
uni- and multivariate analysis of risk factors for end-
points PSC-related death, LT, CCA, and CRC. The
assumption of proportional hazards was tested using
log minus log survival plots and found valid. Risk
factors with a P-value <0.1 in univariate analysis
were entered in the multivariate analysis. Mann-
Whitney’s U-test was performed for comparing con-
tinuous data with a non-normal distribution. The
chi-square test or Fisher’s exact test were used for cat-
egorical data. Statistical analyses were performed
using SPSS v. 19.0 software (SPSS, Inc., Chicago,
IL). P < 0.05 was considered statistically significant.
Results
Study Inclusion. The case-finding strategy yielded
3,020 individuals. Of these, 695 were alive on January
1, 2000 and fulfilled the diagnostic criteria for PSC.
Reasons for study exclusion are depicted in Fig. 1. Five
hundred and ninety PSC patients were resident in the
predefined study area between 2000 and 2007 (Support-
ing Fig. 1). The total number of inhabitants increased
during the study period from 7,342,295 in 2000 to
7,758,980 in 2007. The second PSC cohort, accrued
from the three Dutch transplantation centers outside the
study region, yielded 450 cases, of whom 134 (30%)
were also present in the population-based cohort.5,10,11
Of these, 422 were alive after January 1, 2000 and
entered in the comparison. The IBD control cohort
comprised 722 cases from a population of 271,000.
Patient Characteristics. Main patient characteris-
tics are shown in Table 1. Median follow-up from
diagnosis until death or end of study was 92 months
(range, 0-470). Mean age at diagnosis was 38.9
(standard deviation [SD]: 15.2) years. Among the
590 patients, 375 (64%) were male. Fifty-eight (9%)
patients had small-duct PSC and 23 (4%) fulfilled
the criteria for overlap syndrome with AIH. In total,
402 (68%) PSC patients were diagnosed with IBD.
Overall, 393 (98%) PSC-IBD patients had ulcerative
colitis (UC) or colonic Crohn’s disease (CD) and
only 5 of 78 (6%) CD patients had isolated ileal dis-
ease. Ninety-two percent (493 of 534) of patients
were treated with UDCA, 68% (300 of 438) with
mesalamine, 35% (118 of 333) with thiopurines, and
34% (107 of 317) of patients were using NSAIDs.
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Incidence and Prevalence. Mean annual incidence
between 2000 and 2007 was 0.5 per 100,000 inhabi-
tants (0.6 in men and 0.4 in women). Age- and
gender-standardized incidence rates ranged from 0.25
in female adolescents up to 0.93 per 100,000 in men
between the ages of 40 and 49 (Fig. 2A). On Janu-
ary 1, 2008, point prevalence was 6.0 per 100,000
inhabitants; prevalence rates increased significantly
over time (P < 0.001; Fig. 2B). Net growth in prev-
alence was attributable to increase in incidence and
not to a decrease in number of deaths (data not
shown). In addition, bilirubin levels at diagnosis
did not change between 2000 and 2007 (Supporting
Fig. 2).
Natural History. During follow-up, there were 97
deaths, of which 73 (75%) were PSC related. Sixteen
(3%) patients were lost to follow-up. Estimated
median survival times from diagnosis until the com-
bined endpoint LT (n 5 94) or PSC-related death (n
5 73), until LT, or until PSC-related death were 21.2,
27.0, and 33.6 years, respectively. When including all
deaths in the analysis, the estimated median
Fig. 1. Flowchart patient inclusion.
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transplant-free survival was 20.6 years. Because survival
was considerably longer than previously reported, a
second cohort was accrued consisting of 450 PSC
patients from all three liver transplant centers in the
Netherlands to assess the influence of referral bias.
Notably, the population-based cohort showed a signifi-
cantly longer survival from date of diagnosis until the
combined endpoint LT or PSC-related death, com-
pared to this tertiary referral centers cohort (21.3 ver-
sus 13.2 years; P < 0.0001; Fig. 3).
Patients with small-duct PSC had a much better
survival until PSC-related death or LT, compared with
large-duct PSC (P 5 0.019; Supporting Fig. 3). Con-
currence of AIH did not affect transplant-free survival
(P 5 0.58). PSC patients had a 4-fold increased risk
of mortality, compared to the general population
(SMR, 4.2; 95% confidence interval [CI]: 3.2-5.4).
The four most-frequent causes of death were CCA
(32%), liver failure (18%), OLT-related complications
(9%), and CRC (8%). Ninety-four patients received a
liver transplant after median disease duration of 8.1
years (range, 0.3-31.3). In multivariate analysis, age at
diagnosis, CRC, and CCA were risk factors for end-
point PSC-related death. NSAID use was associated
Table 1. Patient Characteristics
Characteristics
Population-Based
PSC Cohort n (%)
Liver Transplant Centers
PSC Cohort n (%) P Value IBD Cohort n (%) P Value
No. of patients 590 450 722
Male 375 (64) 291 (65) 0.710 310 (43) <0.001
Age at PSC diagnosis, years (mean [SD]) 38.9 (15.2) 36.2 (13.8) 0.004 NA
AIH overlap 23 (4) 47 (10) <0.001 NA
Follow-up (months) (median [range]) 92 (0-470) 80 (0-354) <0.001 98 (0-584) 0.010
IBD 402 (68) 287 (64) 0.140
Ulcerative colitis 308 (77) 224 (78) 0.020 429 (59) <0.001
Crohn’s disease 78 (19) 40 (14) 208 (29)
Unspecified 16 (4) 23 (8) 85 (12)
Age at IBD diagnosis, years (mean [SD]) 31.5 (15.1) 30.2 (14.0) 0.290 41.2 (16.9) <0.001
Abbreviation: NA, not available.
Fig. 2. Age- and gender-specific incidence of PSC (A) and point prev-
alence of PSC per 100,000 inhabitants per year (B) in a population of
7,758,980. Net growth in prevalence was highly significant (P < 0.001).
Fig. 3. Survival until LT or PSC-related death of PSC patients in the
population-based cohort, compared to PSC patients, referred to LT
centers.
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with a decreased risk for the endpoint LT (P 5 0.018;
Table 2).
CCA occurred in 41 of 590 (7%) patients, of
whom 33 died (80%) after a median period of 1 year
(range, 0-7). Median age at CCA diagnosis was 47
years (range, 21-87), and median time between PSC
diagnosis and CCA was 6 years (range, 0-36). All
patients except one had large duct PSC and 27 (66%)
had concomitant IBD, mainly UC. There was a 398-
fold increased risk for developing CCA in PSC
patients compared, to the general population (SIR,
398; 95% CI: 246-608). Five (12%) patients were
diagnosed with PSC and CCA at initial presentation,
another 6 (15%) within the first year, 15 (37%)
between 1 and 10 years, and the remaining 15 (37%)
developed a CCA 10 or more years after PSC diagno-
sis. Cumulative risk of CCA after 10, 20, and 30 years
was 6% (95% CI: 2-15), 14% (95% CI: 4-25), and
20% (95% CI: 6-40), respectively (Fig. 4A). Older age
at PSC diagnosis was an independent risk factor for
endpoint CCA (hazard ratio [HR]: 1.02; 95% CI:
1.00-1.04; P 5 0.049). Occurrence of CRC was a
time-dependent risk factor for CCA (HR, 4.57; 95%
CI: 1.08-19.41; P 5 0.040).
Twenty of five hundred and ninety PSC patients
(3%) developed CRC, of whom 10 died (8 CRC
related and 2 CCA related). Median age at CRC diag-
nosis was 41 years (range, 26-64; Fig. 5). Cumulative
risk of high-grade dysplasia or CRC after 10, 20, and
30 years since PSC diagnosis was 3%, 7%, and 13%,
respectively (Fig. 4A). All CRC patients had large-duct
PSC. There was a 5-fold increased risk for developing
CRC in all PSC patients, compared to the age- and
gender-matched general population (SIR, 5.0; 95%
CI: 2.02-10.3). IBD was present in 19 (95%) patients
(18 UC and 1 CD), and median time between IBD
diagnosis and CRC was 15 years (range, 0-35). One
CRC patient had no endoscopic or histologic signs of
IBD after 14 years of follow-up. Seven (7/722) IBD
control patients developed CRC (SIR, 1.2; 95% CI:
0.3-3.0) after a median time span of 4 years (range,
0-19) after diagnosis (4 UC, 1 CD, and 1 IBD unspe-
cified). There was a 9-fold increased risk for develop-
ing CRC in PSC-UC patients, compared to the age-
and gender-matched population (SIR, 8.6; 95% CI:
3.5-17.7), and a 10-fold increased risk, compared to
UC controls (ratio of SIRs: 9.8; 95% CI: 1.9-96.6).
Strikingly, CRC occurred at a much younger age in
Table 2. Univariate and Multivariate Analyses for Endpoints PSC-Related Death and LT
Endpoint PSC-Related Death
Univariate Analysis Multivariate Analysis
HR 95% CI P Value HR 95% CI P Value
Age at diagnosis 1.05 1.03-1.06 <0.001 1.06 1.02-1.10 0.005
Female gender 1.62 1.01-2.60 0.046 0.62 0.25-1.54 0.300
Small-duct PSC 0.12 0.03-1.44 0.110 Not in model
Concurrence of AIH 0.34 0.05-2.50 0.290 Not in model
Concurrence of IBD 1.16 0.68-1.98 0.590 Not in model
Extension of colitis 1.43 0.62-3.30 0.400 Not in model
CCA 9.51 5.88-15.40 <0.001 8.84 3.63-21.54 <0.001
CRC 3.09 1.55-6.14 0.001 4.26 0.97-18.97 0.056
LT 0.60 0.33-1.08 0.087 1.02 0.44-2.34 0.970
Colectomy 2.04 1.15-3.62 0.014 1.19 0.35-4.06 0.790
UDCA 1.37 0.59-3.18 0.460 Not in model
5-ASA 1.30 0.68-2.49 0.430 Not in model
Thiopurines 0.41 0.18-0.94 0.036 0.82 0.32-2.12 0.680
NSAID 0.28 0.08-0.91 0.035 0.28 0.06-1.33 0.110
Endpoint Liver Transplantation
Age at diagnosis 1.00 0.99-1.02 0.670 1.01 1.00-1.03 0.420
Female gender 0.71 0.45-1.11 0.140 0.57 0.30-1.06 0.074
Small-duct PSC 0.28 0.07-1.13 0.074 0.56 0.14-2.36 0.430
Concurrence of AIH 1.46 0.59-3.64 0.410 Not in model
Concurrence of IBD 1.14 0.71-1.83 0.580 Not in model
Extension of colitis 1.43 0.73-2.78 0.290 Not in model
Colectomy 1.22 0.68-2.20 0.510 Not in model
UDCA 1.60 0.74-3.46 0.240 Not in model
5-ASA 0.60 0.38-0.95 0.029 0.77 0.55-1.28 0.310
NSAID 0.44 0.23-0.85 0.014 0.46 0.22-0.94 0.033
The extended Cox model for time-dependent and -independent variables was used for uni- and multivariate analysis of risk factors for endpoints PSC-related
death, LT, CCA, and CRC. Risk factors with a P-value <0.1 in univariate analysis were entered in the multivariate analysis.
Abbreviation: 5-ASA, 5-aminosalicylic acid.
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PSC-IBD patients (median age: 39; range, 26-64),
compared to IBD controls (59; range, 34-73; P 5
0.019). For PSC-IBD patients, cumulative risk of
CRC after 10, 20, and 30 years since IBD diagnosis
was 1% (95% CI: 0-15), 6% (95% CI: 1-22), and
13% (95% CI: 2-37), respectively (Fig. 4B). Surveil-
lance colonoscopies had been performed before CRC
diagnosis in 53% of PSC-IBD patients with CRC.
When combining PSC-CRC patients from the
population-based and transplantation centers cohorts,
50% (9 of 18) of the nonsurveilled patients and 16%
(3 of 19) who received regular surveillance colonoscop-
ies died of CRC (P 5 0.038; Fig. 4C).
Discussion
Here, we present, by far, the largest population-based
study of PSC with the longest follow-up to date. We
report markedly lower incidence and prevalence rates of
0.5 per 100,000 and 6.0 per 100,000 inhabitants,
respectively, compared to previous studies.17-20 Preva-
lence is rising with stable mortality over time (data not
shown), which is in concordance with a recent system-
atic review and perhaps explained by the rising incidence
of IBD in North-West Europe.17,21,22 Increased inci-
dence could not be explained by earlier diagnosis,
because bilirubin levels at diagnosis remained stable over
time and newer diagnostic modalities were not intro-
duced in the observed period. The difference with previ-
ous studies points to the importance of performing
large, population-based studies in relative rare diseases
to obtain accurate observational data.
Most epidemiological studies on PSC have been
performed in specialized centers, prone for selection
and referral bias. Between 1984 and 2012, only five
small high-quality population-based studies have been
performed reporting incidence rates, ranging from 0 to
1.6 per 100,000 inhabitants, based on a collective
number of only 96 PSC patients.17-20,23,24 When
studying a rare disease in only a few hundred thou-
sand, two or three cases more or less can make a huge
difference on incidence and prevalence rates. In con-
trast, the present results are based on 590 carefully
ascertained PSC patients in all hospitals in a geograph-
ically defined area of almost 8 million inhabitants.
Moreover, by using four different case-finding searches
in each center, we have done our utmost to recruit
every single PSC patient. As an additional case-finding
exercise, all referrals to the three liver transplant cen-
ters in the Netherlands were checked for area of resi-
dence. This resulted in 52 additional patients.
Fig. 4. Malignancy risk in PSC patients and controls. (A) Cumulative
risk of CCA and high-grade colon dysplasia or CRC in PSC patients.
Twenty-two patients with proctocolectomy or CRC before diagnosis of
PSC were excluded from the analysis. (B) Cumulative risk of CRC in
PSC-IBD patients and IBD controls in whom onset of IBD was known.
CD patients with isolated ileitis were excluded from cumulative risk
analysis for CRC. (C) CRC-related mortality in surveilled and nonsur-
veilled PSC-IBD patients.
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Estimated median survival until LT or PSC-related
death found in the present study is much longer, com-
pared to previous reports. When comparing studies on
the natural history of PSC, several factors play an
important role in survival analysis: starting point of
disease; definition of endpoints; and proportion of
patients that underwent LT. Introduction of MRC as a
noninvasive diagnostic tool, physician awareness, and
an increase in routine laboratory blood tests may have
resulted in an earlier detection of the disease over
time. The vast majority of investigators use time of
diagnosis as the starting point for follow-up.1,2,5,8,9
Definition of PSC-related death differs between stud-
ies. Some studies used death from any cause as end-
point for Kaplan-Meier’s analysis.5,7,9,10,25 When we
included all deaths in the analysis, the estimated
median survival until LT or death was 20.6 years. In
three of the largest studies, death from liver disease
was used as an endpoint, excluding death from
CRC.1,2,8 Considering the increased risk for CRC in
PSC, we included CRC-related death in the survival
analysis. However, when the 8 CRC-related deaths
were excluded from analysis, estimated median survival
was 21.3 years, a difference of only 0.1 year. Median
transplant-free survival estimates have been reported in
the last 25 years ranging from 9.3 years up to
18.1,2,5,7-10,25 However, these figures were all based on
cohorts from large referral or LT centers, which may
constitute another important bias. As in our cohort, in
all but one of these studies the starting point for
follow-up was date of diagnosis. In a recent single-
center cohort from Germany reporting a transplant-
free median survival of 9.3 years, 40% of patients had
undergone LT versus 16% in our cohort.9 In the pres-
ent study, we demonstrate the effect of selection bias
by comparing our general population-based cohort
with a cohort comprising all PSC patients, matched
for the population-based cohort inclusion criteria, alive
after January 1, 2000, as well as >518 years at inclu-
sion (n 5 422) from the three transplantation centers
in the Netherlands. This contemporary tertiary referral
cohort, which had a 30% overlap with the population-
based cohort, but immanent by its referral nature not
matched for baseline characteristics (Table 1), showed
an estimated median survival until LT or PSC-related
death of 13.2 years. This figure is in concordance with
the literature, but almost 40% shorter than patients
included in our population-based cohort. These find-
ings highlight the influence of selection bias and hence
again the importance of performing large, population-
based studies to get a reliable estimate of the natural
history of a disease.
The high preponderance of UDCA treatment in
our cohort precluded investigating the influence of this
drug on disease course. However, UDCA was also rou-
tinely prescribed to most patients in the transplant
centers cohort. Moreover, the three largest randomized
studies have not been able to demonstrate a benefit of
UDCA in halting disease progression, although this
does not exclude an effect in early-stage PSC.26-28
Fig. 5. Mean incidence of colorectal carcinoma in PSC patients and the Dutch population.
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The present study describes, for the first time, a
negative association between NSAID use and LT. Most
NSAIDs inhibit cyclooxygenase (COX), an enzyme
that converts arachidonic acid into prostaglandin.
There are some reports that COX-2 is overexpressed
in liver cirrhosis from hepatitis B virus and hepatitis C
virus, as well as in various malignancies, including
HCC.29,30 Interestingly, Chavez et al.31 showed a ben-
eficial effect of acetyl salicylic acid and ibuprofen in an
experimental rat model of liver fibrosis. The NSAIDs
used in this model inhibited oxidative stress, COX-2
activity and nuclear factor kappa B (NF-jB) transloca-
tion to the nucleus. NF-jB plays a central role in the
inflammation-fibrosis-cancer axis in the liver by induc-
ing tumor necrosis factor alpha and interleukin-6 acti-
vating hepatic stellate cells to produce profibrogenic
factors.32 Recently, a large, prospective study showed
that NSAIDs reduced the risk of death resulting from
chronic liver disease, even in individuals who only
used NSAIDs less than two to three times per
month.33 Our finding clearly deserves further
investigation.
Patients with PSC are at highly increased risk for
developing CCA, which has a very dismal prognosis.
Developing surveillance tools for CCA is one of the
prime unmet needs in PSC. CCA was diagnosed
within the first year after diagnosis in 2% of PSC
patients. Thereafter, the cumulative risk of developing
CCA gradually rose to an estimated 20% after 30
years, arguing against a distinct procarcinogenic sub-
phenotype with a high incidence of early CCA.25,34,35
Moreover, it is well known that PSC in retrospect can
have a long subclinical time lag until diagnosis of up
to 38 years (median, 4.3).2
CRC is reported to occur more frequently in IBD
patients than in the general population.36 We observed
that the CRC risk in a population-based IBD cohort is
equal to the general population. In accord with our find-
ings, a study from Denmark showed that CRC risk in
UC patients has declined in the last 30 years and no lon-
ger exceeds that of the general population. However,
this excluded UC patients diagnosed at a young age,
with a long disease duration or concomitant PSC.37
PSC is an additional and independent risk factor for
development of CRC in UC patients, although low
absolute numbers often hamper standardized incidence
ratio analysis, emphasizing the need for large,
population-based cohorts.38-40 Our study confirms the
increased risk for CRC with a 5-fold increase in all PSC
patients, compared to the general population, and a 10-
fold increase in PSC-UC patients, compared to UC
alone. Furthermore, CRC develops, on average, more
than 20 years earlier, compared to IBD patients and the
general population, and ranks among the top four causes
of death in PSC patients, corroborating current guide-
lines to start surveillance every 1-2 years from start of
diagnosis.14,41 PSC-IBD patients whose CRC was dis-
covered in a surveillance program showed a significantly
better outcome.
Limitations of this study lie in its retrospective
nature with its immanent risk of incomplete data sets.
However, the proportion of patients lost to follow-up
was only 3%, and because we focused on rather easy-
to-appreciate endpoints, such as LT, death, and occur-
rence of CCA, we feel that the chance of missing these
data is limited. Also, true population-based figures are
impossible to obtain because PSC is a hospital diagno-
sis. Although we have extensively searched all hospitals
in the predefined geographic area and the potential
tertiary referral hospitals, there is always a chance of
missing some cases and therefore slightly underestimat-
ing incidence and prevalence. The capture-recapture
method, which can correct for this, could not be
applied because three of four data sources were local
databases. Not all PSC patients without clinical signs
of bowel disease have undergone a screening colono-
scopy in the past, which may give an underestimation
of concurrent subclinical IBD.
In conclusion, for accurate assessment of epidemiol-
ogy and natural history of uncommon diseases such as
PSC, extensive population-based studies adhering to rig-
orous case-finding guidelines, such as the Metcalf and
James criteria,12 are indispensable. We found that the
incidence and prevalence rates of PSC are markedly
lower and survival much longer than previously
reported. Notably, the population-based cohort showed
a significantly longer survival until LT or PSC-related
death, compared to a tertiary referral centers cohort,
exemplifying the effect of selection bias. The incidence
of cholangiocarcinoma in PSC patients is high and colo-
rectal carcinoma can develop at a young age, warranting
endoscopic surveillance from the time of diagnosis.
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